Assistant Professor, Department of Surgery, University of California at San Francisco
Dr. Il-Jin Kim is Director of Applied Genomics in the UCSF Thoracic Oncology Program. His work focuses on the identification of novel diagnostic markers and therapeutic targets in various types of human cancers. He is an experienced geneticist for identifying and developing cancer biomarker and companion diagnostics (CDx) for anti-cancer therapeutics (solid and hematological malignancies). Dr. Kim investigates human cancers using state-of-the-art technologies including next-generation sequencing (NGS) and system genetics. Dr. Kim has developed several innovative microarrays (RET, beta-catenin, K-ras, and BRAF) and pioneered new methods of high-throughput mutation screening for which he holds numerous patents. He is also an inventor of the fastest targeted NGS technologies (DNA/RNA extraction, new targeted NGS library prep, NGS data analysis program, and data interpretation tool).
Dr. Il-Jin Kim has identified novel potential diagnostic markers and/or therapeutic targets for human cancers using Integrative Systems Genetics system that he developed with his colleagues, such as PEBP4 (novel type II pneumocyte gene/marker for lung – Nature Commun, 2013), VRK1 (novel cancer-specific mitosis marker and a potential therapeutic target– Nature Commun, 2013), GREM1 (potential lung cancer oncogene and diagnostic marker (lung adenocarcinoma) – Plos One, 2012), SETDB1 (one of the frequently mutated genes and a potential therapeutic target in malignant mesotheliomas –Oncotarget, 2016), and FAIM2 (novel diagnostic marker for SCLC and atypical carcinoids by mRNA expression or IHC and a potential therapeutic target for SCLC- Sci Rep, 2016).
His research and paper for the 'Prediction of response to preoperative chemoradiotherapy in colorectal cancer patients' was named the best publication of 2007 by the journal "Dis Colon Rectum", the award given at the 2008 ASCRS (American Society of Colon and Rectal Surgeons) Annual Meeting. He has also three times received awards for development of innovative genetic and diagnostic assays by AACR (American Association for Cancer Research).
Dr. Il-Jin Kim served as a group leader of the Korean Hereditary Tumor Registry from 2001-2006, an organization of which he has been a member since 1999. As group leader, he led a project that screened approximately 1,000 patients from 400 hereditary cancer families, looking at 12 inherited cancer syndromes. Dr. Kim graduated the College of Veterinary Medicine, Seoul National University with a D.V.M. (Magna Cum Laude), and an M.S. and Ph.D. in Tumor Biology from the College of Medicine at Seoul National University. In 2010, Dr. Kim joined the UCSF faculty in the Department of Surgery.
2012-present: ISRN Biotechnology,
2013-present: Journal of Surgery
College of Veterinary Medicine, Seoul National University, Korea, B.S., D.V.M., 1999, Veterinary Medicine
College of Medicine, Seoul National University, Korea, M.S., 2001, Tumor Biology
College of Medicine, Seoul National University, Korea, Ph.D., 2003, Tumor Biology
College of Medicine, Seoul National University, Korea, Post-doc, 2003-2006, Cancer Genetics
Cancer Research Institute, University of California San Francisco, Post-doc, 2007-2008, Cancer Genetics